Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P2ME
|
|||
| Drug Name |
INO-5401
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Bladder cancer [ICD-11: 2C94; ICD-9: 188] | Phase 2 | [1] | |
| Recurrent glioblastoma [ICD-11: 2A00.00; ICD-10: C71] | Phase 2 | [1], [2] | ||
| Glioblastoma of brain [ICD-11: 2A00.00; ICD-10: C71] | Phase 1/2 | [3] | ||
| Company |
Inovio Pharmaceuticals Plymouth Meeting, PA
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | ClinicalTrials.gov (NCT03491683) INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM). U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.